Introduction
Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory disease characterized by persistent airflow limitation, which is both preventable and treatable. 1 The burden of COPD is considerable and increasing. 2, 3 The severity of COPD is influenced by exacerbations and comorbidities. 4 Spirometry has remained the standard method for confirming a clinical diagnosis of COPD and for assessing COPD severity, 5 but it is now accepted that forced expiratory volume in 1 second (FEV 1 ) is an inadequate marker of the severity of breathlessness, exercise limitation, and health status impairment, 1, 4 although it remains important in the confirmation of a clinical diagnosis of COPD.
The Global initiative for chronic Obstructive Lung Disease (GOLD) strategy document, updated in 2011 and 2013, has proposed a new, multidimensional approach
454
Betsuyaku et al to assess patients with COPD. It recommends that COPD management and treatment should consider both disease impact, determined by assessment of symptoms and activity limitation, and future risk of exacerbations, determined from airflow limitation or exacerbation history. 5, 6 This combined assessment of COPD results in the grouping of patients into one of four categories: (A) low risk, fewer symptoms; (B) low risk, more symptoms; (C) high risk, fewer symptoms; (D) high risk, more symptoms.
For assessing symptoms, GOLD advises utilizing either the COPD Assessment Test (CAT) or the modified Medical Research Council (mMRC) dyspnea scale. The CAT is a simple tool for quantifying the symptoms and impacts of COPD 7, 8 that has been shown to distinguish between different severities of COPD, is highly correlated with the St George's Respiratory Questionnaire (SGRQ) 7 and has been validated in Japan. 9 In Japan, the name recognition of COPD is low, and the majority of these patients have not been diagnosed or appropriately treated. 10 The prevalence of COPD is also underestimated in Japan. 11, 12 These findings highlighted the urgent need for improvements in COPD diagnosis and management in general practice. Most diagnosed patients are treated with bronchodilators such as long-acting β 2 agonists (LABAs) or long-acting antimuscarinics (LAMAs) as monotherapy, and remain symptomatic. 13 It has now been recognized that monotherapy may not enable many patients to achieve the goals of pharmacologic therapy for COPD, namely to control symptoms, improve health status, and reduce the frequency of exacerbations. 1 Guidelines on COPD management recommend the combined use of long-acting bronchodilators and inhaled corticosteroids (ICS) to optimize outcomes, especially exacerbations, in patients with COPD that is inadequately controlled with monotherapy. 1 It has been demonstrated that, in some patients, TRIPLE therapy, in which an anticholinergic is added to an ICS and LABA, has been associated with greater improvements in lung function and quality of life and with reduced rates of hospitalization compared with anticholinergic therapy alone. [13] [14] [15] [16] [17] The aim of this innovative study is to assess the control of COPD using a symptom and exacerbation risk-based treatment strategy according to GOLD 2011. This study has been named the "COPD Symptom-based Management and to Optimise treatment Strategy in Japan" (COSMOS-J) and has been designed to reflect clinical practice in Japan. Unlike a "traditional" randomized controlled trial, treatment in this study is flexible as it tries to reflect clinical practice. This will demonstrate whether the treatment approach outlined in the GOLD strategy document can be used to improve the current management of COPD in Japan. New Japanese guidelines are also anticipated in 2013, which may improve clinical practice. Optimal management of COPD, determined by assessing symptoms using CAT and by assessing the frequency of exacerbations, will be assessed in patients who have been randomized to receive treatment with either salmeterol/fluticasone propionate combination (SFC) or with tiotropium bromide. If optimal management is not achieved on one of these two treatments and patients remain symptomatic or experience an exacerbation, patients have the option to step up to treatment with both drugs, ie, TRIPLE therapy. This paper summarizes the methodology of the study in advance of the publication of the results.
Methods study design
This study is a 24-week, multicenter, randomized, parallelgroup study. Initial study treatments will be double-blind and double-dummy. This study will include a switch treatment strategy for those not adequately controlled on randomized medication. The study aims to recruit 400 patients with moderate-to-severe COPD; 200 patients per treatment arm. After a 4-week run-in period, during which patients will remain on their usual treatment for COPD, patients will be randomized to receive SFC (Adoair™, GlaxoSmithKline KK, Tokyo, Japan) 50/250 µg twice daily delivered via the Diskus™ (GlaxoSmithKline KK) inhalation device, or tiotropium bromide (Spiriva™, Boehringer Ingelheim Pharma GmbH and Co, KG Ingelheim, Germany) 18 µg delivered once daily via the Handihaler™ inhalation device (Boehringer Ingelheim Pharma GmbH and Co), for 24 weeks. SFC 50/250 µg is the licensed dose in Japan. Within the doubledummy study design (Figure 1 ), patients in both groups also receive placebo medication via a matched-placebo inhalation device. Subjects treated with TRIPLE therapy will receive open-label medication. During the run-in, regular treatment with any COPD medications is allowed, except for systemic corticosteroids and antibiotics used for COPD exacerbation. The use of other COPD medication such as antitussives, expectorants, and mucolytics is permitted throughout the study at the investigator's discretion. Salbutamol for use on an as required basis for relief medication, short-term oxygen therapy for treatment of COPD exacerbation, and short-term courses of systemic steroids and/or antibiotics for a COPD exacerbation or adverse event (AE) will also be allowed. 
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Management of COPD using the gOlD 2011 strategy allowed, except for randomized study treatment. If a moderate or severe exacerbation occurs more than once or the CAT score is increased by more than four points after switching to TRIPLE therapy, regular use of COPD medications other than systemic steroids, ICS, β 2 -agonists, and anticholinergic agents is permitted.
study protocol
Post-randomization, patients will be reviewed every 4 weeks to assess their symptom level and the occurrence of any exacerbations ( Figure 1 ). This will be done using the CAT, and asking whether there have been any noticeable changes since the last visit and whether an exacerbation has occurred. FEV 1 and forced vital capacity (FVC) will also be measured at each visit.
Based on the CAT score and presence or absence of exacerbations, at each visit the investigator will ask the subject questions in accordance with the guidance for optimization of COPD treatment (Table 1) . Randomized treatment will be switched to TRIPLE therapy if necessary, having taken the subject's answers and his/her medical course into consideration and having obtained their agreement. The necessity of switching treatments to TRIPLE therapy should be assessed at unscheduled visits, if any, as well as at scheduled visits.
At the first scheduled visit after switching to TRIPLE therapy, TRIPLE therapy should be continued to the next scheduled visit even if there is no improvement in symptoms, since benefits may take more than 1 month to develop.
At the second scheduled visit after switching to TRIPLE therapy, if COPD symptoms are not improved, or if the subject is unsatisfied with the study treatment in spite of switching to TRIPLE therapy, or they have developed side effects due to the added treatment, the investigator should consider changing treatments back to the double-blinded randomized medication. Following a switch back from TRIPLE to the randomized treatment, the physician can return to TRIPLE, if the patient's COPD symptoms justify it or if the subject is unsatisfied with the randomized treatment.
In cases when patients are changed to TRIPLE because of a moderate or severe COPD exacerbation, TRIPLE therapy should be continued throughout the course of the study. The investigator should consider adding other COPD medications or suitable treatment if an exacerbation has occurred more than once during the study or the CAT score has increased more than four points despite switching to TRIPLE therapy. 
Patient participation
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Betsuyaku et al guidelines, 4 with a current or former smoking history of $10 pack years, a post-bronchodilator FEV 1 of $30% to #80% of the predicted normal value, a post-bronchodilator FEV 1 /FVC ratio of ,70%, and a grade of $1 on the mMRC scale. 18 Exclusion criteria for entry to the study include a medical diagnosis of predominant asthma or a respiratory disorder other than COPD that might interfere with the study, lung transplantation and/or lung volume reduction, and a requirement for regular or long-term oxygen therapy. Patients on long-term oxygen therapy would be unlikely to be able to complete the study, with long-term oxygen therapy defined as $12 hours of oxygen a day. Other exclusion criteria include a plan to start or change to a pulmonary rehabilitation program during the study period, regular treatment with oral, parenteral, or depot corticosteroids, a chest X-ray indicating a diagnosis other than COPD, or any other serious, uncontrolled disease likely to interfere with the study. Patients who have received any other investigational drug within 4 weeks of the study are also excluded from the study. As with other anticholinergic drugs, patients with a medical diagnosis of narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction should only be entered at the investigator's discretion.
Randomization is remote and concealed from centers and uses a 1:1 allocation ratio. The primary population for analysis is the modified intent-to-treat (m-ITT) population, which will include all patients randomized to treatment who have received at least one dose of trial medication.
The study is being conducted in accordance with the International Conference on Harmonisation Good Clinical Practice and the 2008 version of the Declaration of Helsinki. All patients must provide a written informed consent form prior to participation. The ethics and review boards of all participating institutions have approved the protocol (GSK study code: SCO116717; NCT01762800). 19 
Efficacy assessments
The primary efficacy endpoint is the proportion of patients who are able to remain on the randomized therapy. Secondary and other efficacy endpoints are listed in Table 2 .
exacerbations
A COPD exacerbation is defined as a sustained worsening of COPD symptoms beyond normal day-to-day variations. The investigator will record all COPD exacerbations throughout the study period in accordance with the classification of exacerbation severity.
• An exacerbation will be classified as a mild exacerbation if treated with relief medication only.
• An exacerbation will be classif ied as a moderate exacerbation if treated with systemic corticosteroids and/ or antibiotics.
• An exacerbation will be classified severe exacerbation if hospitalization is required for treatment of the exacerbation. In this study, both reported and unreported COPD exacerbations will be assessed using the EXAcerbations of Chronic Pulmonary Disease Tool (EXACT). [20] [21] [22] Unreported exacerbations will be determined from symptoms recorded by patients on daily record cards. After the screening visit, subjects will record their respiratory symptoms and physical condition every day. Use of relief medication will also be recorded on the daily record cards.
safety assessment
Safety will be measured by recording any AEs and COPD exacerbations.
statistical analysis
Assuming a 10% to 60% switch rate from the initial treatment group, a 15% difference will be detectable with 86% to 99% power by log-rank test using the planned sample size of 400 subjects.
For the primary comparison of interest, the proportion of patients remaining on randomized therapy (=1-TRIPLE switch rate) and time to switch to TRIPLE will be estimated 
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Management of COPD using the gOlD 2011 strategy by Cox's proportional hazard model. A Kaplan-Meier plot will be prepared.
Descriptive statistics of FEV 1 and CAT scores will be presented. AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by body systems and preferred terms. Serious AEs, drug-related AEs, and events leading to withdrawal will also be summarized.
The primary analysis population will be the m-ITT, which will consist of randomized subjects who received at least a single dose of the investigational product.
Discussion
It is now recognized that the treatment of COPD should involve more than improving lung function since the impact of lung function impairment varies greatly between individual patients. Exacerbations and symptoms also have a significant impact on the health status of these patients. 4, [23] [24] [25] As a result, the GOLD 2011 Strategy Document, updated in 2013, has produced a treatment algorithm based on the assessment of symptoms and exacerbations with the aim of enabling more effective treatment of COPD. 5, 6 However, this strategy has not been tested in a clinical trial, and it is also not clear what proportion and what type of patients can be managed on a single therapy and which should receive multiple therapies. This study will attempt to clarify aspects of this and to determine whether this strategy can improve the management of COPD, particularly in a Japanese setting.
This strategy cannot easily be tested in a usual randomized clinical trial design since this does not reflect real clinical practice (eg, withdrawal from a study often occurs when the study treatment to which the patient is randomized in a blinded manner is judged to be insufficiently effective). Moreover, subject withdrawals from randomized clinical trials are usually the sickest patients who, in real clinical practice, are those who need the most help. 26 A further complication of withdrawals in randomized clinical trials is that this risks a significant study bias. 27 It is known that long-term trials in COPD present difficult problems of design and statistical analysis. 27 In order to test the GOLD strategy, a new type of study design has therefore been introduced. It starts like a usual type of clinical trial with two randomized, blinded arms of appropriate COPD treatments. At each visit, the investigator then assesses the effectiveness of the treatment by assessing symptoms (checking the CAT score, asking the subject how they feel about their treatment using formal study-designed questions, and checking for exacerbation events). The Japanese version of the CAT has been shown to have high reliability and validity for precise assessment of the health status of Japanese patients with COPD. 9 It is important to note that lung function measurements are not used as criteria for treatment change in this study. The primary efficacy endpoint is the proportion of patients who are controlled and able to remain on the randomized therapy. At each assessment point, if the treatment is judged to be satisfactory, the patient's treatment remains unchanged. However, if the treatment is not felt to be effective, instead of the patient having to withdraw or continue on the same therapy but under-treated in terms of their symptoms, the investigator can increase the treatment. This process will occur at each visit and, depending on treatment response, there are options in this study design to maintain, increase, or reduce the treatment as appropriate, thus mimicking clinical practice as far as possible.
TRIPLE therapy, which adds an LAMA to ICS/LABA combinations, has been associated with greater improvements in lung function and quality of life and reduced rates of hospitalization compared with anticholinergic therapy alone. [13] [14] [15] [16] [17] While the efficacy and tolerability of TRIPLE therapy have been evaluated in clinical trials, the effect on COPD outcomes of TRIPLE therapy relative to LAMA and SFC alone has not been assessed outside the confines of a controlled clinical trial.
The strengths of this study design are that a level of treatment flexibility is allowed, which better reflects real clinical practice than a randomized clinical trial and this should also ensure that the sicker patients are not lost from the study. This makes it possible to test the hypothesis behind the GOLD 2011 treatment strategy. The principal weakness in the study design is that when treatment is increased, the blinding will be lost. However, there has to be a compromise to achieve the study objectives and this is probably the best solution. An additional limitation is that the only valid options for treatment are an LAMA or combined LABA/ICS therapy, and that the next obvious step is TRIPLE. However, adding an LABA to an LAMA (without an ICS) may be a valid option for patients not controlled with an LAMA alone in terms of symptoms.
If this study design is successful, the methodology can be used for future studies with new therapies and may complement the standard fixed treatment approach of randomized clinical trials for drug registration purposes. The results of this study will also help physicians to understand if TRIPLE therapy is more effective in controlling symptoms and exacerbations in patients with moderate 
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